Astagraf Xl Capsule, Coated, Extended Release
Product Images NDC 0469-0687

Product Visual Gallery

This gallery contains 12 technical images submitted to the FDA as part of the official labeling for Astagraf Xl (NDC 0469-0687). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Astellas Pharma Us, Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Astellas Logo (Astellas Logo 01)

ASTAGRAF XL tacrolimus extended-release capsules in strength 0.5 mg, packaged in a white and teal box showing capsule imagery with a blue and white coated capsule. The label displays the brand and generic names, the dosage form as coated extended-release capsules for oral use, and the labeler as Astellas Pharma US, Inc.*

FDA Label Image

Astellas Logo (Astellas Logo 02)

ASTAGRAF XL tacrolimus extended-release capsules packaging label. The label shows the product name ASTAGRAF XL, identifies the drug as tacrolimus extended-release capsules, and includes the indication of oral administration. It also displays dosage strengths of 0.5 mg, 1 mg, and 5 mg, and lists Astellas Pharma US, Inc. as the labeler. The label design includes a predominantly white background with some purple and orange elements.*

FDA Label Image

Astellas Logo (Astellas Logo 03)

ASTAGRAF XL tacrolimus extended-release capsules packaging shows 5 mg strength in coated, extended-release capsule form. The label indicates oral use and displays one capsule blister with the brand name ASTAGRAF XL prominently labeled. The product is manufactured by Astellas Pharma US, Inc.*

FDA Label Image

Image 01

ASTAGRAF XL tacrolimus extended-release capsules in a packaging carton measuring 2 ml. The label shows the product name, strength of 1 mg, and capsule dosage form, with branding and labeling by Astellas Pharma US, Inc.*

FDA Label Image

Image 02

ASTAGRAF XL tacrolimus extended-release capsules, coated, in strengths of 0.5 mg, 1 mg, and 5 mg, oral dosage form. The label shows the product name prominently with the description of the extended-release capsules and the labeler Astellas Pharma US, Inc. The package appears as a blister card with three capsules arranged vertically, each capsule marked with its strength.*

FDA Label Image

Image 03 01

The image shows the label of ASTAGRAF XL tacrolimus extended-release capsules in 1 mg strength. The label includes the product name, dosage form as coated extended-release capsules, and strength. It indicates oral administration and is labeled by Astellas Pharma US, Inc. The packaging depicts product identification and dosing information.*

FDA Label Image

Tacrolimus Structural Formula (Image 04)

Chemical structure of tacrolimus, the active ingredient in ASTAGRAF XL tacrolimus extended-release capsules.*

FDA Label Image

Figure 1: Effect Of Co-administered Drugs On The Pharmacokinetics Of Tacrolimus (when Given As Astagraf Xl®) (Image 05)

A pharmacokinetic chart showing the effect of co-administered drugs ketoconazole and rifampin on tacrolimus Cmax and AUC. The x-axis depicts the geometric mean ratio of test to reference with a 90% confidence interval. Test compares Astagraf XL plus co-administered drug to Astagraf XL alone, both given as a single dose.*

FDA Label Image

Figure 2: Effect Of Co-administered Drugs On The Pharmacokinetics Of Tacrolimus (when Given As Immediate-release Tacrolimus) (Image 06)

A chart showing the pharmacokinetic interaction of tacrolimus when co-administered with various drugs including telapravir, boceprevir, magnesium-aluminum hydroxide, voriconazole, and posaconazole. The graph depicts the geometric mean ratio of Cmax and AUC (area under the curve) for tacrolimus compared to when given alone, with 90% confidence intervals plotted on a logarithmic scale.*

FDA Label Image

Astagraf Xl (tacrolimus Extended-release Capsules) 0.5 mg Label (Image 10)

Astellas Pharma US, Inc. packaging for Astagraf XL tacrolimus extended-release capsules, 0.5 mg strength. The carton indicates a once-daily dosing regimen and contains 30 capsules. It includes product and storage information, ingredient details, barcodes, and the Astellas logo. The capsules are coated and intended for oral use.*

FDA Label Image

Astagraf Xl (tacrolimus Extended-release Capsules) 1 mg Label (Image 11)

Packaging label for Astagraf XL 1 mg, tacrolimus extended-release capsules, oral dosage form. The label indicates once-daily dosing, contains 30 capsules per package, and includes manufacturer details: Astellas Ireland Co., Ltd. and marketed by Astellas Pharma US, Inc., Northbrook, IL. The label features warnings, storage instructions, a barcode, and lists inactive ingredients such as lactose monohydrate and magnesium stearate.*

FDA Label Image

Astagraf Xl (tacrolimus Extended-release Capsules) 5 mg Label (Image 12)

Packaging label for Astagraf XL 5 mg tacrolimus extended-release capsules. The label indicates a once-daily oral dosage with 30 capsules per container. It lists Astellas Pharma US, Inc. as the marketer, with manufacturing by Astellas Ireland Co., Ltd. Key details include storage instructions and inactive ingredients. The label features barcodes, dosage instructions, and the Astellas logo.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.